A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.

Trial Details

NCT ID
NCT03311308
Phase
PHASE1
Sponsor
Yana Najjar
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Pembrolizumab Injection [Keytruda]
  • Metformin
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Be willing and able to provide written informed consent for the trial.
  • Have un-resectable (stage III) or advanced (stage IV) melanoma.
  • Be 18 years of age or older on day of signing informed consent
  • Have measurable disease based on RECIST 1.1. Patients without measurable disease may be included on study after discussion with the Sponsor, given …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →